AMNEAL PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax of -$600.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax · last filed 2026-02-27
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2025-06-30 was -$600.00K, a 109.23% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2025-03-31 was $6.40M, a 1.54% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2024-12-31 was $6.60M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2024-09-30 was $6.60M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2024 was $26.20M, a 670.59% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2023 was $3.40M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 12 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2025-06-30 | -$600.00K 10-Q · filed 2025-08-07 | $5.90M 10-Q · filed 2025-08-07 | $12.40M derived: sum of 3 quarters · filed 2026-02-27 | $19.00M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2025-03-31 | $6.40M 10-Q · filed 2025-05-07 | $13.00M derived: sum of 2 quarters · filed 2026-02-27 | $19.60M derived: sum of 3 quarters · filed 2026-02-27 | $26.10M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-12-31 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $13.20M derived: sum of 2 quarters · filed 2026-02-27 | $19.70M derived: sum of 3 quarters · filed 2026-02-27 | $26.20M 10-K · filed 2026-02-27 | -$26.20M 10-K · filed 2025-02-28 |
| 2024-09-30 | $6.60M 10-Q · filed 2024-11-12 | $13.10M derived: sum of 2 quarters · filed 2024-11-12 | $19.60M 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $6.50M 10-Q · filed 2024-08-09 | $13.00M 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $6.50M 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $3.40M 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |